Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019.
作者信息
Malkovsky Miroslav
机构信息
Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
出版信息
J Infect Dis. 2020 Jul 6;222(3):509-510. doi: 10.1093/infdis/jiaa312.
Abstract
摘要
相似文献
1
Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019.治疗性血浆置换-中和抗体联合疗法治疗重症2019冠状病毒病
J Infect Dis. 2020 Jul 6;222(3):509-510. doi: 10.1093/infdis/jiaa312.
2
Response to Malkovsky.对马尔科夫斯基的回应。
J Infect Dis. 2020 Jul 6;222(3):510-511. doi: 10.1093/infdis/jiaa313.
3
Prolonged shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) RNA among patients with coronavirus disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）RNA的长期脱落
Infect Control Hosp Epidemiol. 2020 Oct;41(10):1235-1236. doi: 10.1017/ice.2020.307. Epub 2020 Jun 24.
4
Re: Seah et al.: Assessing viral shedding and infectivity of tears in Coronavirus disease 2019 (COVID-19) patients (Ophthalmology. 2020;127:977-979).回复： Seah等人：评估2019冠状病毒病（COVID-19）患者泪液中的病毒脱落和传染性（《眼科学》。2020年；127：977 - 979）。
Ophthalmology. 2020 Nov;127(11):e103-e104. doi: 10.1016/j.ophtha.2020.05.040. Epub 2020 May 25.
5
Kinetics of viral load and antibody response in relation to COVID-19 severity.病毒载量和抗体反应动力学与 COVID-19 严重程度的关系。
J Clin Invest. 2020 Oct 1;130(10):5235-5244. doi: 10.1172/JCI138759.
6
Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series.治疗性血浆置换作为2019冠状病毒病患者的挽救治疗：病例系列
Pol Arch Intern Med. 2020 May 29;130(5):455-458. doi: 10.20452/pamw.15340. Epub 2020 May 7.
7
Neutralizing Antibodies Against SARS-CoV-2-Important Questions, Unclear Answers.针对严重急性呼吸综合征冠状病毒2的中和抗体——重要问题，答案不明
JAMA Intern Med. 2020 Oct 1;180(10):1362. doi: 10.1001/jamainternmed.2020.4624.
8
Reply.回复。
Ophthalmology. 2020 Nov;127(11):e104-e105. doi: 10.1016/j.ophtha.2020.05.041. Epub 2020 May 25.
9
Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.治疗性血浆置换作为脓毒性休克的常规疗法以及作为新冠病毒病的实验性治疗方法：我们并不确定。
Crit Care. 2020 May 15;24(1):226. doi: 10.1186/s13054-020-02943-1.
10
Will antibody tests for the coronavirus really change everything?新冠病毒抗体检测真的会改变一切吗？
Nature. 2020 Apr;580(7805):571-572. doi: 10.1038/d41586-020-01115-z.
本文引用的文献
1
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.宿主对 SARS-CoV-2 的失衡反应导致 COVID-19 的发生。
Cell. 2020 May 28;181(5):1036-1045.e9. doi: 10.1016/j.cell.2020.04.026. Epub 2020 May 15.
2
A human monoclonal antibody blocking SARS-CoV-2 infection.一种人源单克隆抗体阻断 SARS-CoV-2 感染。
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
3
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.新冠肺炎患者恢复期血浆疗法对病毒脱落和生存的影响。
J Infect Dis. 2020 Jun 16;222(1):38-43. doi: 10.1093/infdis/jiaa228.
4
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.针对 SARS-CoV-2 和其他人类冠状病毒的中和抗体。
Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.
5
A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19.一种针对新型冠状病毒的新型治疗方法：支持对暴发性新型冠状病毒肺炎使用治疗性血浆置换的观点。
Crit Care. 2020 Apr 2;24(1):128. doi: 10.1186/s13054-020-2836-4.
6
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
7
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.鉴定 2019 新型冠状病毒的受体结合域（RBD）：作为病毒附着抑制剂和疫苗开发 RBD 蛋白的意义。
Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19.
8
Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers.早期治疗性血浆置换在感染性休克中的应用：一项关注安全性、血液动力学、血管屏障功能和生物标志物的前瞻性开放标签非随机初步研究。
Crit Care. 2018 Oct 30;22(1):285. doi: 10.1186/s13054-018-2220-9.
Zotero 插件